KineMed Inc. ( www.kinemed.com ) announced today that Dr. Patrizia Fanara, Vice President of Neuroscience, will present at the 5th Neurodegenerative Conditions Research and Development Conference on Sept 22nd, 2011 in San Francisco, CA, at 10.10am.
Dr. Fanara's presentation entitled "Novel Biomarkers that Monitor Brain Changes in Neurodegeneration and Translate into Humans" will discuss how KineMed's neuronal pathway-based biomarker approach has advanced the field of biomarker research and treatment of neurodegenerative disorders. Dr. Fanara will focus on KineMed's use of non-radioactive isotopic labeling to compare changes in the kinetics of biochemical processes between healthy and diseased states, thereby identifying pathways that are causal in pathogenesis.
"We will be presenting advances that represent a new future in this field through an unprecedented ability to measure not just one molecule but an entire pathway, and the flux of proteins within that pathway. This enables us to look directly into the immense complexity of neuronal function in vivo and obviates the need to create simplified disease models, with their inherent weaknesses. We are providing our collaborators with a rich and powerful toolset that reveals causal disease processes in their early stages, identifies trackable biomarkers and precisely measures the effects of drug perturbation on disease progression. KineMed is continuing to advance techniques that can therefore be applied both to the detection of neurological disorder and to the development of truly disease-modifying, effective therapeutic strategies to address Parkinson's, Alzheimer's, Huntington's, ALS and other neurodegenerative conditions," said Dr. Patrizia Fanara, Vice President of Neuroscience.
Dr. Fanara's presentation will provide an overview of:
Rational and exploratory biomarker discovery approaches through putative linkage with pathways relevant to neurodegeneration; Real-time indices of neuronal dysfunction and reparative processes; Ability to measure dynamic biological and biochemical processes occurring in neurodegeneration and to move quickly from animal studies to human trials; Information gained about the disease process from brain chemistry signatures from neurons and other cell types in humans that can be back-translated to preclinical models; Biomarkers that can be useful to clarify disease mechanisms and to discover new diagnostic biomarkers and therapeutic targets.
SOURCE: KineMed, Inc.
For more information, please visit: http:/ www.gtcbio.com
No comments:
Post a Comment